News & Updates

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

Daily supplementation with melatonin, zinc, and multivitamins cuts the duration of COVID-19 or COVID-19-like symptoms, thus supplementing the COVID-19 treatment armamentarium, a study has shown.

Daily use of the oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant to prevent migraine is associated with a favourable safety profile and sustained improvements in efficacy outcomes, according to the 52-week data from an ongoing, open-label, 156-week safety extension study.